Whiteside T L, Herberman R B
Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania 15213, USA.
Clin Diagn Lab Immunol. 1994 Mar;1(2):125-33. doi: 10.1128/cdli.1.2.125-133.1994.
Natural killer (NK) cells, the CD3- CD56+ CD16+ subset of peripheral blood lymphocytes, have long been known to be involved in non-major histocompatibility complex-restricted natural immunity to virally infected and malignant target cells. The association of abnormalities in NK cell numbers or functions with a broad spectrum of human diseases has been more clearly defined in recent years as a result of the improved knowledge of NK cell physiology and advances in monitoring of NK cell functions in health and disease. The ability to reliably measure changes in NK activity and/or numbers during the course of disease or response to treatment has focused attention on the role of the NK cell in disease pathogenesis. The improved understanding of NK cell deficiency in disease has opened a way for therapies specifically designed to improve NK cell function. The therapeutic use of biologic response modifiers capable of augmenting NK cell activity in vivo and of adoptive transfer of highly enriched, activated autologous NK cells in diseases such as cancer and AIDS is being evaluated. The importance of NK cells in health and the consequences of NK cell deficiency or excess are likely to be more extensively monitored in the future.
自然杀伤(NK)细胞是外周血淋巴细胞中CD3-CD56+CD16+亚群,长期以来已知其参与对病毒感染和恶性靶细胞的非主要组织相容性复合体限制的天然免疫。近年来,由于对NK细胞生理学的认识提高以及健康和疾病中NK细胞功能监测的进展,NK细胞数量或功能异常与多种人类疾病的关联得到了更明确的界定。在疾病过程中或对治疗的反应中可靠测量NK活性和/或数量变化的能力,使人们将注意力集中在NK细胞在疾病发病机制中的作用上。对疾病中NK细胞缺陷的更好理解为专门设计用于改善NK细胞功能的疗法开辟了道路。目前正在评估能够在体内增强NK细胞活性的生物反应调节剂以及在癌症和艾滋病等疾病中过继转移高度富集、活化的自体NK细胞的治疗用途。未来,NK细胞在健康中的重要性以及NK细胞缺陷或过剩的后果可能会得到更广泛的监测。